

ASX RELEASE

30 April 2019

4C Quarterly Cash Flow Report

Amplia Therapeutics Limited (ASX Code: ATX) has today released its Appendix 4C – Quarterly Cashflow report for the period ended 31 March 2019.

The cash balance as at 31 March 2019 was \$1,241,000. Cash outflows during the quarter totalled \$340,000, being significantly less than the \$888,000 cash outflow forecast on 29 January 2019. In particular, actual Research and Development expenditure was \$394,000 less than the previously projected amount of \$555,000 for the quarter. The difference arose from payment timing factors and not a reduction in planned R&D activity.

The total estimated cash outflow for the quarter ending 30 June 2019 is \$895,000 of which \$612,000 relates to projected Research and Development expenditure. This expenditure includes a number of non-recurring costs included in the previous quarters R&D cash outflow estimates which were not paid during that quarter. These items including dose range finding studies and production scale up. Core Administration, corporate, and staff cost are estimated to average \$80,000 per month or \$239,000 for the quarter to 30 June 2019.

By 30 June 2019 the Company expects to have completed dose range finding studies required to support the formal toxicology programme. The Company expects also to have also received one kilogram of clinical grade AMP945 drug substance to support the toxicology programme and also the Phase I healthy volunteer study planned for early next year. Preclinical studies to evaluate suitable combinations of drug candidates AMP886 and AMP945 with already approved oncology treatments are ongoing.

- End

For Further Information

Simon Wilkinson, CEO

+64 21 661 850

www.ampliatx.com

Suite 226, 55 Flemington Road, North Melbourne, VIC 3051

Email info@ampliatx.com

www.ampliatx.com

Appendix 4C

Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

Name of entity

Amplia Therapeutics Limited

ABN

16 165 160 841

Quarter ended ("current quarter")

31 March 2019

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (12 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers		
1.2 Payments for		
(a) research and development	<161>	<325>
(b) product manufacturing and operating costs		
(c) advertising and marketing		
(d) leased assets		
(e) staff costs	<118>	<615>
(f) administration and corporate costs	<39>	<366>
1.3 Dividends received (see note 3)		
1.4 Interest received	5	20
1.5 Interest and other costs of finance paid		
1.6 Income taxes paid		
1.7 Government grants and tax incentives		
1.8 Other		
Intellectual property costs	<29>	<121>
R&D tax refund	-	218
Refund of trial deposits	-	225
Miscellaneous	2	<23>
1.9 Net cash from / (used in) operating activities	<340>	<987>

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (12 months) \$A'000
2. Cash flows from investing activities		
2.1 Payments to acquire:		
(a) property, plant and equipment	-	<3>
(b) businesses (see item 10)		
(c) investments		
(d) intellectual property		
(e) other non-current assets		
2.2 Proceeds from disposal of:		
(a) property, plant and equipment		
(b) businesses (see item 10)		
(c) investments		
(d) intellectual property		
(e) other non-current assets		
2.3 Cash flows from loans to other entities		
2.4 Dividends received (see note 3)		
2.5 Other (provide details if material)		
2.6 Net cash from / (used in) investing activities	-	<3>

3. Cash flows from financing activities		
3.1 Proceeds from issues of shares		
3.2 Proceeds from issue of convertible notes		
3.3 Proceeds from exercise of share options		
3.4 Transaction costs related to issues of shares, convertible notes or options	-	<12>
3.5 Proceeds from borrowings		
3.6 Repayment of borrowings		
3.7 Transaction costs related to loans and borrowings		
3.8 Dividends paid		
3.9 Other (provide details if material)		
3.10 Net cash from / (used in) financing activities	-	<12>

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of quarter/year to date	1,582	2,229
4.2	Net cash from / (used in) operating activities (item 1.9 above)	<340>	<987>
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	<3>
4.4	Net cash from / (used in) financing activities (item 3.10 above)	-	<12>
4.5	Effect of movement in exchange rates on cash held	<1>	14
4.6	Cash and cash equivalents at end of quarter	1,241	1,241

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	202	283
5.2	Call deposits	1,039	1,229
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	1,241	1,582

6.	Payments to directors of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to these parties included in item 1.2	66
6.2	Aggregate amount of cash flow from loans to these parties included in item 2.3	-
6.3	Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2	

This item includes payments to the CEO for remuneration totalling NZ\$53,077 (i.e. A\$50,675) for the quarter and \$15,000 to an entity associated with the Director/Secretary for the provision of company secretarial services

7. Payments to related entities of the entity and their associates	Current quarter \$A'000
7.1 Aggregate amount of payments to these parties included in item 1.2	
7.2 Aggregate amount of cash flow from loans to these parties included in item 2.3	
7.3 Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2	

8. Financing facilities available <i>Add notes as necessary for an understanding of the position</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
8.1 Loan facilities		
8.2 Credit standby arrangements		
8.3 Other (please specify)		
8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.		


9. Estimated cash outflows for next quarter	\$A'000
9.1 Research and development	<612>
9.2 Product manufacturing and operating costs	-
9.3 Advertising and marketing	-
9.4 Leased assets	-
9.5 Staff costs	<148>
9.6 Administration and corporate costs	<91>
9.7 Other	
Intellectual property costs	<44>
9.8 Total estimated cash outflows	<895>

10. Acquisitions and disposals of business entities (items 2.1(b) and 2.2(b) above)	Acquisitions	Disposals
10.1 Name of entity		
10.2 Place of incorporation or registration		
10.3 Consideration for acquisition or disposal		
10.4 Total net assets		
10.5 Nature of business		

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Sign here:



(Director)

Date: 30 April 2019

Print name: Simon Wilkinson

Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
2. If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.